Prof. Dr. med. et phil. nat. Markus Jörger
chief of service
Medizinische Onkologie und Hämatologie · Dept. I
Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
Wyss N, Berner F, Walter V, Jochum A, Purde M, Abdou M, Sinnberg T, Hofmeister K, Pop O, Hasan A, Bauer J, Cheng H, Lütge M, Klümper N, Diem S, Kosaloglu-Yalcin Z, Zhang Y, Sellmer L, Macek B, Karbach J, König D, Läubli H, Zender L, Meyer B, Driessen C, Schürch C, Jochum W, Amaral T, Heinzerling L, Cozzio A, Hegazy A, Schneider T, Brutsche M, Sette A, Lenz T, Walz J, Rammensee H, Früh M, Jäger E, Becher B, Tufman A, Núñez N, Jörger M, Flatz L. Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade. Am J Respir Crit Care Med 2024; 210:919-930.
Oct 1, 2024Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
Oct 1, 2024Am J Respir Crit Care Med 2024; 210:919-930
Wyss Nina, Berner Fiamma, Walter Vincent, Jochum Ann-Kristin, Purde Mette T, Abdou Marie-Therese, Sinnberg Tobias, Hofmeister Kathrin, Pop Oltin, Hasan Ali, Bauer Jens, Cheng Hung-Wei, Lütge Mechthild, Klümper Niklas, Diem Stefan, Kosaloglu-Yalcin Zeynep, Zhang Yizheng, Sellmer Laura, Macek Boris, Karbach Julia, König David, Läubli Heinz, Zender Lars, Meyer Britta S, Driessen Christoph, Schürch Christian M, Jochum Wolfram, Amaral Teresa, Heinzerling Lucie M, Cozzio Antonio, Hegazy AhN, Schneider Tino, Brutsche Martin, Sette Alessandro, Lenz Tobias L, Walz Juliane Sarah, Rammensee Hans-Georg, Früh Martin, Jäger Elke, Becher Burkhard, Tufman Amanda, Núñez Nicolás Gonzalo, Jörger Markus, Flatz Lukas
HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.
Besse A, Sedlarikova L, Büchler L, Kraus M, Yang C, Strakova N, Soucek K, Navratil J, Svoboda M, Welm A, Jörger M, Driessen C, Besse L. HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer. Br J Cancer 2024
Jul 5, 2024HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.
Jul 5, 2024Br J Cancer 2024
Besse Andrej, Sedlarikova Lenka, Büchler Lorina, Kraus Marianne, Yang Chieh-Hsiang, Strakova Nicol, Soucek Karel, Navratil Jiri, Svoboda Marek, Welm Alana L, Jörger Markus, Driessen Christoph, Besse Lenka
Electrodiagnostic Biomarkers in Paraneoplastic Retinopathy.
Gougoulakis L, Rothermundt C, Flynn M, Jörger M, Todorova M. Electrodiagnostic Biomarkers in Paraneoplastic Retinopathy. Klin Monbl Augenheilkd 2024; 241:510-524.
Apr 23, 2024Electrodiagnostic Biomarkers in Paraneoplastic Retinopathy.
Apr 23, 2024Klin Monbl Augenheilkd 2024; 241:510-524
Gougoulakis Laura Sophie, Rothermundt Christian, Flynn Marie-Claire, Jörger Markus, Todorova Margarita
SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.
Digklia A, Kollár A, Felber Dietrich D, Kronig M, Britschgi C, Rordorf T, Jörger M, Krasniqi F, Metaxas Y, Colombo I, Ribi K, Rothermundt C. SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial. Eur J Cancer 2023; 197:113470.
Dec 9, 2023SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.
Dec 9, 2023Eur J Cancer 2023; 197:113470
Digklia Antonia, Kollár Attila, Felber Dietrich Denise, Kronig M N, Britschgi Christian, Rordorf Tamara, Jörger Markus, Krasniqi Fatime, Metaxas Yannis, Colombo Ilaria, Ribi Karin, Rothermundt Christian
Geriatric evaluation methods in oncology and their use in clinical studies: A systematic literature review.
Stueger A, Jörger M, De Nys K. Geriatric evaluation methods in oncology and their use in clinical studies: A systematic literature review. J Geriatr Oncol 2023:101684.
Dec 9, 2023Geriatric evaluation methods in oncology and their use in clinical studies: A systematic literature review.
Dec 9, 2023J Geriatr Oncol 2023:101684
Stueger Amelie, Jörger Markus, De Nys Katelijne
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
Bauer T, Santoro A, Lin C, Garrido-Laguna I, Jörger M, Greil R, Spreafico A, Yau T, Goebeler M, Hütter-Krönke M, Perotti A, Juif P, Lu D, Barys L, Cremasco V, Pelletier M, Evans H, Fabre C, Doi T. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors. J Immunother Cancer 2023; 11
Nov 29, 2023Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
Nov 29, 2023J Immunother Cancer 2023; 11
Bauer Todd M, Santoro Armando, Lin Chia-Chi, Garrido-Laguna Ignacio, Jörger Markus, Greil Richard, Spreafico Anna, Yau Thomas, Goebeler Maria-Elisabeth, Hütter-Krönke Marie Luise, Perotti Antonella, Juif Pierre-Eric, Lu Darlene, Barys Louise, Cremasco Viviana, Pelletier Marc, Evans Helen, Fabre Claire, Doi Toshikiko
C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework.
Nassar Y, Ojara F, Pérez-Pitarch A, Geiger K, Huisinga W, Hartung N, Michelet R, Holdenrieder S, Jörger M, Kloft C. C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework. Cancers (Basel) 2023; 15
Nov 15, 2023C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework.
Nov 15, 2023Cancers (Basel) 2023; 15
Nassar Yomna M, Ojara Francis Williams, Pérez-Pitarch Alejandro, Geiger Kimberly, Huisinga Wilhelm, Hartung Niklas, Michelet Robin, Holdenrieder Stefan, Jörger Markus, Kloft Charlotte
Early Identification of Patients at Risk of Cabazitaxel-induced Severe Neutropenia.
Agema B, Buck S, Viskil M, Isebia K, de Neijs M, Sassen S, Koch B, Jörger M, de Wit R, Koolen S, Mathijssen R. Early Identification of Patients at Risk of Cabazitaxel-induced Severe Neutropenia. Eur Urol Oncol 2023
Nov 2, 2023Early Identification of Patients at Risk of Cabazitaxel-induced Severe Neutropenia.
Nov 2, 2023Eur Urol Oncol 2023
Agema Bram C, Buck Stefan A J, Viskil Mano, Isebia Khrystany T, de Neijs Micha J, Sassen Sebastiaan D T, Koch Birgit C P, Jörger Markus, de Wit Ronald, Koolen Stijn L W, Mathijssen Ron H J
Non-pharmaceutical interventions to optimize cancer immunotherapy.
Bösch M, Baty F, Rassouli F, Kowatsch T, Jörger M, Früh M, Brutsche M. Non-pharmaceutical interventions to optimize cancer immunotherapy. Oncoimmunology 2023; 12:2255459.
Sep 28, 2023Non-pharmaceutical interventions to optimize cancer immunotherapy.
Sep 28, 2023Oncoimmunology 2023; 12:2255459
Bösch Maximilian, Baty Florent, Rassouli Frank, Kowatsch Tobias, Jörger Markus, Früh Martin, Brutsche Martin
EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy.
Amaral T, Pop O, Chatziioannou E, Sinnberg T, Niessner H, Zhao J, Ring S, Jörger M, Schroeder C, Armeanu-Ebinger S, Cozzio A, Leiter U, Thomas I, Jochum W, Garbe C, Forchhammer S, Levesque M, Mangana J, Hölzel M, Dummer R, Schürch C, Forschner A, Flatz L. EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy. J Am Acad Dermatol 2023; 89:1072-1074.
Jul 22, 2023EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy.
Jul 22, 2023J Am Acad Dermatol 2023; 89:1072-1074
Amaral Teresa, Pop Oltin Tiberiu, Chatziioannou Eftychia, Sinnberg Tobias, Niessner Heike, Zhao Jing Hua, Ring Sandra Stephanie, Jörger Markus, Schroeder Christopher, Armeanu-Ebinger Sorin, Cozzio Antonio, Leiter Ulrike, Thomas Ioannis, Jochum Wolfram, Garbe Claus, Forchhammer Stephan, Levesque Mitchell Paul, Mangana Joanna, Hölzel Michael, Dummer Reinhard, Schürch Christian M, Forschner Andrea, Flatz Lukas
Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer.
Omlin A, Cathomas R, von Amsberg G, Reuter C, Feyerabend S, Loidl W, Boegemann M, Lorch A, Heidenreich A, Tsaur I, Larcher-Senn J, Buck S, Mathijssen R, Jaehde U, Gillessen S, Jörger M. Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 2023; 29:1887-1893.
May 15, 2023Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer.
May 15, 2023Clin Cancer Res 2023; 29:1887-1893
Omlin Aurelius, Cathomas Richard, von Amsberg Gunhild, Reuter Christoph, Feyerabend Susan, Loidl Wolfgang, Boegemann Martin, Lorch Anja, Heidenreich Axel, Tsaur Igor, Larcher-Senn Julian, Buck Stefan A J, Mathijssen Ron H J, Jaehde Ulrich, Gillessen Silke, Jörger Markus
A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients.
Ojara F, Henrich A, Frances N, Nassar Y, Huisinga W, Hartung N, Geiger K, Holdenrieder S, Jörger M, Kloft C. A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients. CPT Pharmacometrics Syst Pharmacol 2023; 12:1714-1725.
Feb 27, 2023A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients.
Feb 27, 2023CPT Pharmacometrics Syst Pharmacol 2023; 12:1714-1725
Ojara Francis Williams, Henrich Andrea, Frances Nicolas, Nassar Yomna M, Huisinga Wilhelm, Hartung Niklas, Geiger Kimberly, Holdenrieder Stefan, Jörger Markus, Kloft Charlotte
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
Jörger M, Hundsberger T, Haefliger S, von Moos R, Hottinger A, Kaindl T, Engelhardt M, Marszewska M, Lane H, Roth P, Stathis A. Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study. Invest New Drugs 2023; 41:267-275.
Feb 16, 2023Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
Feb 16, 2023Invest New Drugs 2023; 41:267-275
Jörger Markus, Hundsberger Thomas, Haefliger Simon, von Moos Roger, Hottinger Andreas F, Kaindl Thomas, Engelhardt Marc, Marszewska Michalina, Lane Heidi, Roth Patrick, Stathis Anastasios
HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy.
Zděblová Čermáková Z, Hurník P, Konvalinka D, Štembírek J, Paračková T, Resová K, Cvek J, Blažek T, Knybel L, Formánek M, Gachechiladze M, Jörger M, Soltermann A, Škarda J, Motyka O, Janoutová J. HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy. Medicina (Kaunas) 2023; 59
Feb 14, 2023HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy.
Feb 14, 2023Medicina (Kaunas) 2023; 59
Zděblová Čermáková Zuzana, Hurník Pavel, Konvalinka David, Štembírek Jan, Paračková Tereza, Resová Kamila, Cvek Jakub, Blažek Tomáš, Knybel Lukáš, Formánek Martin, Gachechiladze Mariam, Jörger Markus, Soltermann Alex, Škarda Jozef, Motyka Oldřich, Janoutová Jana
Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
Berner F, Bomze D, Lichtensteiger C, Walter V, Niederer R, Hasan Ali O, Wyss N, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Abdou M, Diem S, Knöpfli S, Sinnberg T, Hofmeister K, Cheng H, Toma M, Klümper N, Purde M, Pop O, Jochum A, Pascolo S, Jörger M, Früh M, Jochum W, Rammensee H, Läubli H, Hölzel M, Neefjes J, Walz J, Flatz L. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. Sci Immunol 2022; 7:eabn9644.
Sep 2, 2022Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
Sep 2, 2022Sci Immunol 2022; 7:eabn9644
Berner Fiamma, Bomze David, Lichtensteiger Christa, Walter Vincent, Niederer Rebekka, Hasan Ali Omar, Wyss Nina, Bauer Jens, Freudenmann Lena Katharina, Marcu Ana, Wolfschmitt Eva-Maria, Haen Sebastian, Gross Thorben, Abdou Marie-Therese, Diem Stefan, Knöpfli Stella, Sinnberg Tobias, Hofmeister Kathrin, Cheng Hung-Wei, Toma Marieta, Klümper Niklas, Purde Mette-Triin, Pop Oltin Tiberiu, Jochum Ann-Kristin, Pascolo Steve, Jörger Markus, Früh Martin, Jochum Wolfram, Rammensee Hans-Georg, Läubli Heinz, Hölzel Michael, Neefjes Jacques, Walz Juliane, Flatz Lukas
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
Schmulenson E, Bovet C, Theurillat R, Decosterd L, Largiadèr C, Prost J, Csajka C, Bärtschi D, Guckenberger M, von Moos R, Bastian S, Jörger M, Jaehde U. Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). Br J Clin Pharmacol 2022; 88:5336-5347.
Jul 23, 2022Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
Jul 23, 2022Br J Clin Pharmacol 2022; 88:5336-5347
Schmulenson Eduard, Bovet Cédric, Theurillat Regula, Decosterd Laurent Arthur, Largiadèr Carlo R, Prost Jean-Christophe, Csajka Chantal, Bärtschi Daniela, Guckenberger Matthias, von Moos Roger, Bastian Sara, Jörger Markus, Jaehde Ulrich
Characteristics and survival of patients with cancer with intended off-label use-a cohort study.
Schmitt A, Walter M, Herbrand A, Jörger M, Moffa G, Novak U, Hemkens L, Kasenda B. Characteristics and survival of patients with cancer with intended off-label use-a cohort study. BMJ Open 2022; 12:e060453.
May 24, 2022Characteristics and survival of patients with cancer with intended off-label use-a cohort study.
May 24, 2022BMJ Open 2022; 12:e060453
Schmitt Andreas Michael, Walter Martin A, Herbrand Amanda Katherina, Jörger Markus, Moffa Giusi, Novak Urban, Hemkens Lars G, Kasenda Benjamin
Clinical Implementation of Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland.
Begré U, Jörger M, Aebi S, Amstutz U, Largiadèr C. Clinical Implementation of Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland. Front Pharmacol 2022; 13:885259.
May 18, 2022Clinical Implementation of Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland.
May 18, 2022Front Pharmacol 2022; 13:885259
Begré Ursina B M, Jörger Markus, Aebi Stefan, Amstutz Ursula, Largiadèr Carlo R
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA).
Jörger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt A, Cantoni N, Caspar C, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz J, Kopp C, Hayoz S, Stathis A, von Moos R, Swiss Group for Clinical Cancer Research (SAKK). Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). Cancers (Basel) 2022; 14
Apr 27, 2022Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA).
Apr 27, 2022Cancers (Basel) 2022; 14
Jörger Markus, Metaxas Yannis, Zaman Khalil, Michielin Olivier, Mach Nicolas, Bettini Adrienne, Schmitt Andreas M, Cantoni Nathan, Caspar Clemens B, Stettler Sonja, Malval Roma, Pless Miklos, Britschgi Christian, Renner Christoph, Koeberle Dieter, Schulz Jessica D, Kopp Christoph, Hayoz Stefanie, Stathis Anastasios, von Moos Roger, Swiss Group for Clinical Cancer Research (SAKK)
C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer.
Klümper N, Saal J, Berner F, Lichtensteiger C, Wyss N, Heine A, Bauernfeind F, Ellinger J, Brossart P, Diem S, Schmid S, Jörger M, Frueh M, Ritter M, Hölzel M, Flatz L, Bald T. C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer. J Immunother Cancer 2022; 10
Mar 1, 2022C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer.
Mar 1, 2022J Immunother Cancer 2022; 10
Klümper Niklas, Saal Jonas, Berner Fiamma, Lichtensteiger Christa, Wyss Nina, Heine Annkristin, Bauernfeind Franz Georg, Ellinger Jörg, Brossart Peter, Diem Stefan, Schmid Sabine, Jörger Markus, Frueh Martin, Ritter Manuel, Hölzel Michael, Flatz Lukas, Bald Tobias